Gilat Received Over $4 Million Order from the US Department of Defense
October 28, 2024 07:02 ET
|
Gilat Satellite Networks Ltd.
PETAH TIKVA, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services,...
Gilat Satellite Networks Awarded Over $5M in Support of the US Department of Defense
September 16, 2024 07:03 ET
|
Gilat Satellite Networks Ltd.
PETAH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced...
Gilat Awarded Over $9M to Support Critical Connectivity Requirements for the US Department of Defense
July 02, 2024 07:11 ET
|
Gilat Satellite Networks Ltd.
PETAH TIKVA, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced...
Gilat Awarded Over $5 Million Order from the US Department of Defense
April 03, 2024 07:04 ET
|
Gilat Satellite Networks Ltd.
PETAH TIKVA, Israel, April 03, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced...
Gilat Awarded $5 Million Order from the US Department of Defense
March 28, 2024 07:06 ET
|
Gilat Satellite Networks Ltd.
PETAH TIKVA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services,...
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
July 26, 2022 06:00 ET
|
Immuron Limited
MELBOURNE, Australia, July 26, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic
May 11, 2022 06:00 ET
|
Immuron Limited
Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical trials to be conducted. One trial will focus on...
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
May 09, 2022 06:00 ET
|
Immuron Limited
UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the...
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
April 19, 2022 07:33 ET
|
Immuron Limited
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
January 12, 2022 06:00 ET
|
Immuron Limited
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to...